Pharma & Bio
Technology
[K-Bio’s Expansion into Japan] (1) Trust Over Low Prices… Remsima Tops the Charts in Japan 11 Years After Entry
Celltrion(068270) Celltrion’s flagship biosimilar, “Remsima,” has surpassed the original drug to become the top-prescribed medication in Japan. While Remsima has rapidly expanded its market presence, …
Lifestyle
ABL Bio Inc. Facing Allegations of Unfair Trading: The Key Question Is Whether the CEO Was Involved… Is a Trading Suspension Possible?
ABL Bio Inc.(298380) As news spreads that CEO Lee Sang-hoon’s family is also implicated in allegations of trading based on insider information, anxiety is growing among shareholders who invested in AB…
Technology
QuantaMatrix Incorporated Becomes ‘Qumico’… What Is the ‘Two-Track Synergy’ Strategy Developed with MiCo Ltd.?
(Graphic: ChatGPT)
QuantaMatrix Incorporated(317690)is expanding its collaboration with MiCo Ltd. under the new brand name “QMiCo.” This two-track strategy involves growing “dRAST,” a rapid antibi…
Lifestyle
Why HANS BIOMED CORPORATION Is Increasing Its Stake in A-Tems… The Value of ‘A-Paste-C’
HANS BIOMED CORPORATION(042520)is expanding its stake in its affiliate, A-Tems, with the aim of maximizing investment returns on A-Tems’ core pipeline. Given that A-Tems possesses technology and exper…
Technology
Opacalim Clinical Trials Paused… A Closer Look at the Preconditions for SK BIOPHARMACEUTICALS’s 2.3 Trillion Won Deal
SK BIOPHARMACEUTICALS(326030)has drawn attention by repeatedly emphasizing that the deal to acquire “Opacalym” (BHV-7000), a new drug candidate for epilepsy, from the U.S. biotech company Biohaven is …
Technology
SK BIOPHARMACEUTICALS’ Cenobamate: How Far Will ‘Supply Expansion’ Go? Impact of Increased Prescriptions in the U.S.?
(Graphic: ChatGPT)
SK BIOPHARMACEUTICALS(326030)The value of internal supply contracts for “cenobamate” (brand name Xcopri), an epilepsy treatment supplied by SK Life Science to its U.S. subsidiar…
Lifestyle
Kang Seong-min, CEO of PeopleBio, Inc.: “Full-Scale Launch of LDT and Diagnostic Kit Business in the U.S. … Revenue to Become Apparent Starting Next Year”
“Building on our designation as an innovative medical device by the U.S. Food and Drug Administration (FDA), we plan to establish a local subsidiary within this year. Next year, we will launch laborat…
Lifestyle
Orum Therapeutics, Inc. Reeling from BMS Technology Return… Sole Clinical Pipeline Disappears [Bio Spotlight]
On the 17th, stock prices in the biotech sector saw mixed results due to business restructuring and technology development issues at major companies. #Orum Therapeutics, Inc. plummeted by over 33% in …
Technology
Orum Loses Its Only Clinical Asset After BMS Withdraws[K-Bio Pulse]
Biotech stocks moved in sharply different directions on Sept. 17 as investors reacted to corporate restructuring and drug development updates.Orum Therapeutics plunged more than 33% in after-hours tra…
Technology
[Exclusive] Genomictree Inc. Receives NMPA Approval in China for Colorectal Cancer Diagnostic Kit
It has been confirmed that a product developed based on Genomictree Inc.(228760)’s early-stage colorectal cancer diagnostic technology has received marketing authorization from China’s National Medica…